Y. Tanaka

A phase I study of vorinostat combined with bortezomib in Japanese patients with relapsed or refractory multiple myeloma

M. Ogura, K. Tobinai, T. Uchida, 2015, International Journal of Hematology.

Pembrolizumab plus axitinib versus sunitinib in metastatic renal cell carcinoma: outcomes of Japanese patients enrolled in the randomized, phase III, open-label KEYNOTE-426 study

B. Rini, S. Anai, Y. Tomita, 2021, International Journal of Clinical Oncology.

Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial

D. Bajorin, H. Nishiyama, J. Bellmunt, 2019, International Journal of Clinical Oncology.

A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma

W. Au, Y. Matsuno, M. Ogura, 2014, British journal of haematology.